RZLT

Rezolute, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website rezolutebio.com
Employees(FY) 57
ISIN US76200L3096

Performance

-5.39%

-11.31%

-8.92%

+13.14%

+342.32%

YTD

+387.78%

Profile

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Advanced Technical Analysis

Technical Analysis of RZLT 2024-12-20

The Moving Average Score of 23 indicates a bearish sentiment, while the Oscillators Score of 56 suggests a neutral outlook, and the overall Technical Score of 40 reinforces a neutral stance. Collectively, these scores imply a cautious market sentiment, with potential for volatility but lacking strong bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of RZLT

Stock Rank

Recent News & Updates

2024-12-04 19:00
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-12-02 19:00
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism(Globenewswire)
2024-11-07 03:05
Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update(Yahoo Finance)
2024-11-04 19:00
Rezolute to Participate in Upcoming Investor Conferences(Globenewswire)
2024-09-19 04:05
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update(Globenewswire)
2024-09-08 19:30
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study(Globenewswire)
2024-08-26 20:00
Rezolute to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-04 19:30
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism(Globenewswire)
2024-07-30 20:00
Rezolute to Participate in the BTIG Virtual Biotechnology Conference(Globenewswire)
2024-06-26 20:00
Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement(Globenewswire)
2024-06-23 20:00
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds(Globenewswire)
2024-06-13 19:30
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-06-13 11:30
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-06-13 04:01
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-05-29 20:00
Rezolute to Participate in the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-21 19:23
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday(Investorplace)
2024-05-21 18:27
Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk(Fiercebiotech)
2024-05-21 04:05
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)(Globenewswire)
2024-05-15 10:54
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024(Investorplace)
2024-05-15 04:05
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update(Globenewswire)
2024-04-22 20:00
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting(Globenewswire)
2024-03-20 02:33
Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More(Insidermonkey)
2024-03-05 18:30
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)(Globenewswire)
2024-02-13 03:05
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update(Globenewswire)
2024-01-23 19:00
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer(Globenewswire)
2024-01-22 19:00
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism(Globenewswire)
2023-12-13 19:00
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism(Globenewswire)
2023-12-12 19:00
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME )(Globenewswire)
2023-11-23 22:14
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS'(Newsfilecorp)
2023-11-16 19:00
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.